Genflow Strengthens IP Portfolio

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has filed a formal request for the examination of its patent application entitled SIRT6 Variants for NASH in China.

The application covers proprietary variants of the SIRT6 gene designed to address Non-Alcoholic Steatohepatitis (NASH), a severe progressive liver disease with limited treatment options. By pursuing examination in China, Genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide.

• Eric Leire, CEO of Genflow, commented: "The filing of this examination request in China represents another significant step in protecting our technology in one of the world's largest healthcare markets. We are committed to advancing our research into SIRT6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH."